The first phase 3 trial of the injectable hepcidin mimetic, called VERIFY, has met all its primary and secondary objectives, ...

Eisai and Biogen have been unable to persuade the medicines regulator in Australia to approve their Alzheimer's disease ...

GSK has joined a lengthening list of companies that have paused diversity, equity, and inclusion (DEI) targets under pressure ...

A long-acting Factor VIII replacement therapy for haemophilia A from Sobi and Sanofi has been recommended for use by the NHS ...

The Windsor Framework marks a significant change in the UK's post-Brexit regulatory space, particularly for the ...

As such, the 2nd Peptide Formulation & Delivery Innovation Summit (June 24 - 26, 2025 | Boston, MA) returns as the only ...

GUB014295 is a subcutaneously administered long-acting amylin agonist that also stimulates calcitonin receptors, according to ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

As the demands of modern healthcare grow, new therapies are introduced at record speeds, and guidelines are quickly updated, it is key that medical education evolves to keep up. Traditional ...

Novel analytical methodologies, real-world data (RWD), innovative trial designs, and new technologies are crucial to optimise ...

The Interministerial Commission for the Pricing of Medicines in Spain has backed access by the Spanish National Health System ...

Unique, patient-focused manufacturing models are needed to scale up innovative cell therapies for cancer and one company, ...